NANOVIRICIDES, INC. — Director's Dealing 2011

Feb 18, 2011

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NANOVIRICIDES, INC. (NNVC.OB)
CIK: 0001379006
Period of Report: 2011-02-15

Reporting Person: Diwan Anil (Director, President, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2011-02-15	Common Stock	G	2117800	—	Disposed	7882200	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Options	$		Common Stock (1000000)	1000000	Direct
Series A Convertible Preferred Stock	$		Common Stock (1000000)	1000000	Direct

Footnotes

F1: Represents shares of common stock given as gifts to five immediate family members, each receiving an amount equal to 426,560 shares of common stock.

F2: Not applicable: no derivative securities were converted or exercised.

F3: Includes option exerciseable into 1,000,000 shares of common stock owned by Anil Diwan.

F4: Includes Series A Convertible Preferred Stock exercisable into 1,000,000 shares of common stock and contractual right to received 250,000,000 additional Series A Convertible Preferred Stock each on March 1, 2011, 2012 and 2013. Anil Diwan, the Company's President and Chairman, also serves as the CEO and Director of TheraCour Pharma Inc. and owns approximately 70% of the outstanding capital stock of TheraCour. Anil Diwan has both investment and dispositive power over the NanoViricides shares held by TheraCour Pharma, Inc. Does not include 33,006,018 shares of common stock and 7,000,000 shares of the Company's Series A Convertible Preferred Stock.